http://bluediamondcondom.com/clinically-proven-through-science/ Blue diamond® condoms have been clinically proven to maximize firmness and hardness by stimulating blood flow within the penis. In an independently conducted study comparing blue diamond® condoms against a standard condom, 74% of men who expressed a preference between the two condoms said that the blue diamond® condom gave them a firmer erection. In the same study 72% of the female partners who expressed a preference also noticed an increase in the firmness of their partner’s penis and 63% felt that as a result of their partner using the blue diamond® condom they enjoyed a longer lasting sexual experience.
UK publicity begining
Spot the flaws in those stats, I am sure they are correct but read between the lines - the fine detail They don't tell you nothing but don't they sound good.
It's interesting that investors are now starting to recognise what an incredible portfolio this company has! The scenario that goldust88 puts forward doesn't just apply to a single product, Futura has several which have similar possibilities. Buy, buy, buy as at 40p it's a steal . . . . . . . .
1 Apr '15
Looks like they are slowly building a substantial position. Now above 16% nice to see the professionals taking an interest.this share will suddenly bloom maybe sooner than later
29 Mar '15
Pain relief products-the winner ?
from iii Futura advised that the pain relief portfolio has recieved interest from all the major pharmacuetical companies but they were not negotiating with them until after the trials which they are very confident would confirm the effectiveness of the product. It seems to me that this could be even more exciting than CSD and when results are out-June/July a bidding war may be on the cards for the rights. Its quite possible that this could raise more money than the current market capital of the company. Or even 2-3 times that. Voltarol the rights to which it would be competing against was valued at $129 million dollars. See http://www.wikinvest.com/stock/Endo_Pharmaceuticals_Holdings_%28ENDP%29/Novartis Under the terms of the five-year Voltaren® Gel Agreement, Endo made an upfront cash payment of $85 million. Endo has agreed to pay royalties to Novartis AG on annual Net Sales of the Licensed Product, subject to certain thresholds as defined in the Voltaren® Gel Agreement. In addition, Endo has agreed to make certain guaranteed minimum annual royalty payments of $30 million per year payable in the fourth and fifth year of the Voltaren® Gel Agreement, subject to certain limitations as defined in the Voltaren® Gel Agreement. These guaranteed minimum royalties will be creditable against royalty payments on a Voltaren® Gel Agreement year basis such that Endo’s obligation with respect to each Voltaren® Gel Agreement year is to pay the greater of (i) royalties payable based on annual net sales of the Licensed Product or (ii) the guaranteed minimum royalty for such Voltaren® Gel Agreement year. No royalty payments were payable to Novartis during the three months ended March 31, 2009 or 2008. Novartis is also eligible to receive a one-time milestone payment of $25 million if annual net sales of Voltaren® Gel exceed $300 million in the U.S. The $85 million upfront payment and the present value of the guaranteed minimum royalties have been capitalized as an intangible asset in the amount of $129.0 million, representing the fair value of the exclusive license to market Voltaren® That's a lot of money!
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.